Get the Stockscreener App
2.92
5.04%
0.14
After Hours:
2.90
-0.02
-0.68%
Erasca Inc stock is traded at $2.92, with a volume of 1.65M.
It is up +5.04% in the last 24 hours and up +22.69% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$2.78
Open:
$2.78
24h Volume:
1.65M
Relative Volume:
1.03
Market Cap:
$828.44M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-3.561
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
+13.18%
1M Performance:
+22.69%
6M Performance:
+139.34%
1Y Performance:
+12.31%
1-Day Range:
$2.751
$3.00
1-Week Range:
$2.52
$3.075
52-Week Range:
$1.01
$3.30
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
2.92 | 788.72M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Initiated | Stifel | Buy |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Understanding Erasca Inc.’s price movementPortfolio Risk Summary & High Yield Equity Trading Tips - newser.com
Will Erasca Inc. stock benefit from automation2025 Earnings Surprises & Real-Time Volume Trigger Notifications - newser.com
Erasca Inc. stock chart pattern explainedJuly 2025 Market Mood & Safe Swing Trade Setups - newser.com
Why Erasca Inc. stock remains on watchlistsWeekly Stock Analysis & Free Weekly Watchlist of Top Performers - newser.com
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - GlobeNewswire
ErascaTargeting Cancer's Most Commonly Mutated Pathway - RTTNews
Analyzing Precision BioSciences (NASDAQ:DTIL) and Erasca (NASDAQ:ERAS) - Defense World
HC Wainwright Issues Optimistic Estimate for Erasca Earnings - Defense World
Heatmap analysis for Erasca Inc. and competitorsEarnings Overview Summary & Short-Term Swing Trade Alerts - newser.com
Analyzing net buyer seller activity in Erasca Inc.July 2025 Gainers & Free Growth Oriented Trading Recommendations - newser.com
Using fundamentals and technicals on Erasca Inc.IPO Watch & Risk Managed Investment Signals - newser.com
HC Wainwright Comments on Erasca’s Q1 Earnings (NASDAQ:ERAS) - Defense World
Why Erasca Inc. stock could see breakout soonTrade Performance Summary & AI Optimized Trade Strategies - newser.com
Is Erasca Inc. stock poised for growthQuarterly Growth Report & Weekly Top Performers Watchlists - newser.com
Erasca, Inc. Reports Q3 2025 Financial Results - MSN
Guggenheim raises Erasca stock price target to $5 on pipeline progress By Investing.com - Investing.com South Africa
Brokerages Set Erasca, Inc. (NASDAQ:ERAS) Price Target at $4.00 - Defense World
Erasca, Inc. (ERAS) stock price, news, quote and history - Yahoo Finance UK
Will Erasca Inc. stock maintain growth storyWeekly Volume Report & Daily Profit Focused Screening - newser.com
Analyzing drawdowns of Erasca Inc. with statistical tools2025 Trading Volume Trends & Real-Time Market Sentiment Alerts - newser.com
Guggenheim Maintains Erasca (ERAS) Buy Recommendation - Nasdaq
Guggenheim raises Erasca stock price target to $5 on pipeline progress - Investing.com Australia
Erasca price target raised to $5 from $3 at Guggenheim - TipRanks
How to forecast Erasca Inc. trends using time seriesJuly 2025 Catalysts & Daily Risk Controlled Trade Plans - newser.com
What analysts say about Erasca Inc stockShort Selling Opportunities & Identify Winning Stocks - earlytimes.in
Stifel reiterates Buy rating on Erasca stock, maintains $6 price target - Investing.com Canada
Erasca reports Q3 EPS (11c), consensus (10c) - MSN
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):